Sana_Logo_RGB-72_Blue.png
Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
December 12, 2021 09:05 ET | Sana Biotechnology, Inc
Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells CD8- and CD4-targeted fusosomes generated functional...
Sana_Logo_RGB-72_Blue.png
Sana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates
November 08, 2021 16:05 ET | Sana Biotechnology, Inc
Announced license agreement for Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs Q3 2021 cash position of $866.1 million SEATTLE, Nov. 08, 2021 (GLOBE...
Sana_Logo_RGB-72_Blue.png
Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting
November 04, 2021 09:07 ET | Sana Biotechnology, Inc
SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be...
Sana_Logo_RGB-72_Blue.png
Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs
October 19, 2021 09:00 ET | Sana Biotechnology, Inc
Agreement combines Beam’s gene editing technology with Sana’s ex vivo platform SEATTLE, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and...
Sana_Logo_RGB-72_Blue.png
Sana Biotechnology to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 07, 2021 16:05 ET | Sana Biotechnology, Inc
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana_Logo_RGB-72_Blue.png
Sana Biotechnology Reports Second Quarter 2021 Financial Results and Business Updates
August 04, 2021 16:05 ET | Sana Biotechnology, Inc
Presented data showing immune evasion and survival after transplantation of allogeneic cells into primates without immune suppression at ISSCR 2021 Entered long-term lease to establish manufacturing...
Sana_Logo_RGB-72_Blue.png
Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Candidates
July 14, 2021 16:10 ET | Sana Biotechnology, Inc
Facility to Support Allogeneic CAR T, Gene Therapy, and Stem Cell-Derived Therapies Facility Able to Support Clinical Trial and Early Commercial Launches of Multiple Programs State-of-the-Art...
Sana_Logo_RGB-72_Blue.png
Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates
June 26, 2021 10:42 ET | Sana Biotechnology, Inc
First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression Transplanting allogeneic cells into a...
Sana_Logo_RGB-72_Blue.png
Sana Biotechnology to Present During Plenary Sessions at ISSCR 2021 Virtual Annual Meeting
June 14, 2021 09:15 ET | Sana Biotechnology, Inc
SEATTLE , June 14, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be...
Sana_Logo_RGB-72_Blue.png
Sana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
June 02, 2021 16:05 ET | Sana Biotechnology, Inc
SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...